A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

As a result, mergers with larger pharma companies and alliances with academia are simply a part of that reality. And to be fair, some biotech organizations build themselves in a manner designed to ...

Rensselaer Polytechnic Institute (RPI) has announced a partnership with Rensselaer County to create a business accelerator.

PROVEN 360 will provide strategic support to SABCO focused on enhancing its visibility and engagement within the UAE and ...

NCBiotech offers a continuum of programs that translate ideas to create and support companies from inception to launch and ... Training programs, academic institutions, and support organizations ...

A federal judge will soon decide whether to dismiss a lawsuit against UnitedHealth Group alleging that the company and its ...

Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index ...

Biotech firm Phytome Life Sciences plans to establish a headquarters in Saudi Arabia in a bid to accelerate commercialization ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...